An inhibitor of sodium glucose co-transporter type 2 (SGLT-2) is recommended in type 2 diabetes mellitus (DM) but its use is still undetermined in tacrolimus (TAC)-induced DM. We evaluated the effect of empagliflozin (Em) on TAC-induced pancreatic islet dysfunction and renal injury in an experimental model of TAC-induced DM and in vitro. TAC induced a twofold increase in SGLT-2 expression, while Em decreased SGLT-2 expression and further increased urinary glucose excretion compared to the TAC group. Em reduced hyperglycemia and increased plasma insulin level, pancreatic islet size, and glucose-stimulated insulin secretion compared to the TAC group. In kidney, Em alleviated TAC-induced renal dysfunction and decreased albumin excretion and histological injury compared with the TAC group. Increased oxidative stress and apoptotic cell death by TAC was remarkably decreased with Em in serum and pancreatic and renal tissues. In in vitro study, TAC decreased cell viability and increased reactive oxygen species (ROS) production in both insulin-secreting beta-cell derived (INS-1) and human kidney-2 (HK-2) cell lines. Addition of Em increased cell viability and decreased ROS production in HK-2 but not in INS-1 cell lines. This suggests that Em is effective in controlling TAC-induced hyperglycemia and has direct protective effect on TAC-induced renal injury.
Introduction
New-onset diabetes mellitus (DM) after transplantation (NODAT) is a serious complication after kidney transplantation and is associated with poor patient and graft survival (1) (2) (3) . Among several risk factors of NODAT, immunosuppressive drugs used in transplantation increase the occurrence risk of NODAT (4) . Tacrolimus (TAC) is the most commonly used immunosuppressive agent. However, long-term treatment with TAC is associated with an increased incidence of NODAT (5) . This condition is partly related to the direct toxic effect of TAC on pancreas islet cells, and oxidative stress plays a pivotal role in TAC-induced pancreas dysfunction (6, 7) .
The guideline for NODAT management is based on type 2 DM (8) . Metformin is recommended as a first-line drug for type 2 DM, and addition of a second-line drug is suggested to achieve better control of hyperglycemia. Among them, sodium glucose co-transporter type 2 (SGLT-2) inhibitor is a new type of antidiabetic drug and exerts its effect by preventing glucose reabsorption in renal tubular cells (9, 10) . It addition to its effective control of hyperglycemia, a recent clinical trial revealed that SGLT-2 inhibitor has cardiovascular and renal protective effect in type 2 DM (11) . Therefore, SGLT-2 inhibitor may be useful in renal transplant patients with NODAT, but its use is still undetermined.
In this study, we aimed to evaluate the effect of SGLT-2 inhibitor on TAC-induced DM. First, we tested whether empagliflozin (Em) has a blood glucose-lowering effect in TAC-induced DM. Second, we evaluated the protective effect of Em on TAC-induced kidney and pancreatic islet injury using an experimental model of TAC-induced DM and in vitro study.
Materials and Methods

Animals and drugs
The experiment protocol (CUMC-2016-0101-01) was approved by the animal care committee at the Catholic University of Korea. Male SpragueDawley rats (Charles River Technology, Seoul, Korea) weighing 200 to 220 g were housed in individual cases and allowed free access to a lowsalt diet (0.05% sodium; Teklad Premier, Madison, WI) and tap water (12) . TAC (Prograf; Astellas Pharma, Ibaraki, Japan) was diluted in olive oil (Sigma, St Louis, MO) to a final concentration of 1.5 mg/kg. Em (Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany) was diluted in drinking water to a final concentration of 5 or 10 mg/kg.
Experimental design
After acclimatization and a low-salt diet for 1 week, weight-matched rats were randomized to 6 groups containing 12 rats each and were treated daily with TAC (1.5 mg/kg, subcutaneously [s.c.]) or vehicle (VH, olive oil, 0.3 mL, s.c.) for 3 weeks. After confirming development of TAC-induced DM, Em (5 and 10 mg/kg, oral gavage) was added for 3 weeks more. Control rats were treated with Em only. The dose and duration of treatment was chosen based on a previous report (13, 14) . Additional study was performed to evaluate the early effect of Em on TAC-induced renal dysfunction by adding Em to TAC for 1 week.
Basic protocol
Rats were pair-fed and their body weight was monitored daily. After the treatment period, animals were housed individually in metabolic cages (Tecniplast, Gazzada, Italy), and their urine volume and water intake were measured over 24 h. Animals were anesthetized, and blood samples and tissue specimens were obtained. Measurement of serum electrolyte concentrations, urine glucose, and albuminuria was performed using enzymatic colorimetric methods (Modular DPP system; Roche, Hamburg, Germany). Serum creatinine (Scr) was measured using a quantitative enzyme colorimetric method (Stanbio Laboratory, Boerne, TX). Creatinine clearance (Clcr) was calculated from 24 h of urine collections and serum using a standard formula. Systolic blood pressure (SBP) was recorded in conscious rats by the tail-cuff method with plethysmography (15). The whole blood TAC level was measured using liquid chromatography-mass spectrometry/mass spectrometry (16) .
Preservation of kidney and pancreatic tissues and isolated islets
Kidney and pancreas tissue was preserved by in vivo perfusion through the abdominal aorta. The animals were perfused with 0.01 mol/L phosphate-buffered saline and dissected kidney and pancreases were immersed in periodate-lysine-2% paraformaldehyde solution and embedded in paraffin.
Measurement of pancreatic islet function
The intraperitoneal glucose tolerance test (IPGTT) was performed at the end of the treatment period, as previously described (17) , and the area under the curve of glucose (AUCg) was calculated by trapezoidal estimation from the values obtained in the IPGTT. The plasma insulin level was measured in duplicate by an enzyme-linked immunosorbent assay kit (Millipore Corporation, St. Charles, MO); pancreatic islets from rats were isolated and glucose-stimulated insulin secretion (GSIS) was performed based on the previous study (18) .
Measurement of insulin mRNA in pancreases
Total RNA was extracted from the obtained islets using RNAzol reagent (TEL-TEST, Friendwood, TX). First-strand cDNA was reverse-transcribed from RNA using random hexanucleotide primers. First Strand Synthesis Kit for reverse transcription-polymerase chain reaction (RT-PCR; Roche Diagnostics, Scandinavia AB, Bromma, Sweden) using 2 lg of total RNA was used for the synthesis of cDNA. RT-PCR for insulin/b-actin was performed as described previously (19) . The specific PCR primers used were b actin (Forward: 5 0 -GTCGTACCACTGGCATTGTG; Reverse: 5 0 -CTCTCAGC TGTGGTGGTG AA) and insulin (Forward: 5 0 -GTACCTGGTGTGTGGGGAAC;
Reverse: 5 0 -CCAGTTGGTAGAGGGAGCAG).
Measurement of interstitial fibrosis and glomerular injury in kidney
Histological assessment of tubule interstitial fibrosis (TIF) in trichromestained tissue sections was performed as described previously (20) . The extent of fibrosis was estimated by counting the percentage of injured area per field using a polygon program. Glomerular injury was assessed with mesangial matrix area, podocyte number, and integrity. The mesangial matrix area was detected by periodic acid-Schiff staining and was quantified for each glomerular cross-section (21) . Podocyte number was evaluated with immunohistochemistry of Wilms tumor (WT1) and was presented as the number of WT1-positive cells per 91000 view in 20 random glomeruli. We also evaluated the podocyte integrity with electron microscopic observation (22) .
Immunohistochemistry
Immunohistochemistry was performed as described previously (23 
Immunoblot analysis
Immunoblot analysis was performed as described previously (24) . In situ TdT-mediated dUTP-biotin nick-end labeling assay 
Immunofluorescence analysis
We performed immunofluorescence analysis 8-OHdG and caspase-3 expression in the pancreas tissues. The primary antibodies used were insulin, 8-OHdG, and caspase-3. The secondary antibodies were conjugated to Alexa fluor 647 (AffiniPure) and Cy3 (Affini Pure, West Grove, PA). The nuclear counterstain, 4 0 6 0 -diamidino-2-phenylindole (DAPI; Invitrogen, Carlsbad, CA), was also used. Twenty different fields in each section at 9400 magnification were analyzed using a color image analyzer (TDI Scope Eye Version 3.0 for Windows).
Measurement of serum and urine 8-OHdG level
Oxidative DNA damage was assessed by measuring the level of the DNA adduct 8-OHdG in serum and urine using a competitive enzyme-linked immunosorbent assay (Cell Biolabs, San Diego, CA).
Measurement of cell viability
Human kidney-2 (HK-2) cells and insulin-secreting beta-cell-derived line (INS-1) cells were seeded into 96-well plates at a density of 2.5 9 10 4 and 5 9 10 4 cells/well, respectively, and pre-incubated for 24 h in an incubator at 37°C. After 24 h, the culture medium was changed to serum-free medium containing TAC (50 lg/mL) and Em (10, 50, 100, and 500 nM). Cell viability was assayed using a Cell Counting Kit-8 assay kit (Dojin Laboratories, Kumamoto, Japan) according to the manufacturer's protocol (25) .
Flow cytometry
Flow cytometry was performed to assess reactive oxygen species (ROS) production. HK-2 cells were seeded into 6-well plates at a density of 2.5 9 10 5 cells/well and preincubated for 24 h at 37°C in an incubator.
After 24 h, the culture medium was changed to serum-free medium containing TAC (50 lg/mL) and Em (10, 50, 100, and 500 nM). The method was performed as described previously (26) .
Statistics
The date is expressed as means AE standard error of at least three independent experiments. Multiple comparisons between groups were performed by one-way analysis of variance with the Bonferroni post hoc test (SPSS software version 19.0; IBM, Armonk, NY). Statistical significance was assumed as p < 0.05. Table 1 lists the changes in the functional basic parameters. Em treatment decreased body weight compared with the VH and TAC group without Em treatment. TAC increased urine volume, water intake, and urine albumin excretion but addition of Em recovered three parameters.
Results
Effect of Em on basic parameters
There was no significant difference in the electrolyte content, SBP, and trough level of TAC in the whole blood.
Effect of Em on glucose transporter expression and urinary glucose excretion in TAC-induced DM Figure 1 shows the effect of Em on SGLT-2 expression and urinary glucose excretion in TAC-induced DM. TAC increased immunoreactivity and twofold increase of SGLT-2 expression compared to the VH group in kidney tissues (2.2 AE 0.1 vs. 1.0 AE 0.1, p < 0.05). However, Em decreased SGLT-2 expression compared with the TAC group in a dose-dependent manner (Em5: 1.6 AE 0.1, Em10:
1.5 AE 0.5, p < 0.05) ( Figure 1A and B). TAC increased urinary glucose compared to the VH group (198 AE 26 vs. 0 AE 0 mg/g, p < 0.05) and Em further increased urinary glucose compared to the TAC group (Em5: 610 AE 70, Em10: 683 AE 63 mg/g, p < 0.05) ( Figure 1C ). Effect of Em on pancreatic islet size, insulin mRNA expression, and insulin secretion in TAC-induced DM The TAC group showed a smaller islet with lower intensity of insulin staining within islet than the VH group (7.4 AE 1.8 vs. 15.5 AE 0.8 lm 2 9 10 3 , p < 0.05), but Em increased the islet size compared with the TAC group (Em10: 13.7 AE 1.0 lm 2 9 10 3 , p < 0.05) ( Figure 4A and B). The insulin mRNA in the TAC group was significantly reduced compared with the VH group (60.7 AE 3.1 vs. 100.0 AE 0.7, p < 0.05). However, Em increased insulin mRNA expression compared with the TAC group (Em10: Figure 4D ). Table 2 shows the effect of Em on TAC-induced renal dysfunction. The TAC group demonstrated increased Scr and decreased Clcr compared to the VH group. However, addition of Em to TAC for 1 week improved renal Effect of Em on TAC-induced glomerular injury TAC significantly increased fractional mesangial area (16.9 AE 2.1 vs. 6.0 AE 1.1 %, p < 0.05), and decreased WT1-positive cell (11.3 AE 0.7 vs. 22.0 AE 1.1, p < 0.05). Em reduced fractional mesangial area (Em5: 13.1 AE 1.1, Em10: 11.1 AE 0.6 %, p < 0.05) and increased WT1-positive cell (Em10: 16.1 AE 0.5, p < 0.05) (Figure 6A-D) . EM study revealed that TAC caused fusion of foot process but Em preserved podocyte structure ( Figure 6A-E) . Effect of Em on TAC-induced oxidative stress and apoptosis in kidney and pancreatic islet 8-OHdG, the marker of oxidative stress, was much higher in the TAC group than in the VH group in serum 
Influence of Em on renal function in TAC-induced renal injury
Differential effect of Em on TAC-induced pancreatic islet and renal tubular cells injury in vitro
The viability of both HK-2 cells and INS-1 cells significantly decreased in the TAC group compared with the VH group. Em increased cell viability in a dose-dependent manner in HK-2 cell lines but not in INS-1 cell lines (Figure 10A and B) . To determine whether the protective effect of Em is related to oxidative stress, we measured the ROS production in HK-2 cell by flow cytometry. TAC significantly increased ROS production compared with the VH group (41.6 AE 2.3 vs. 0.2 AE 0.01%, p < 0.05), but Em reduced TAC-induced ROS production in a dosedependent manner (Em100: 18.1 AE 2.7 %, Em500: 17.8 AE 2.5 %, p < 0.05) (Figure 10C and D) .
Discussion
The present study was undertaken to investigate whether Em is effective in TAC-induced DM. The results clearly show that Em improves not only in TAC-induced hyperglycemia but also renal injury. Furthermore, Em has a direct effect on TAC-induced renal injury via a glucoseindependent mechanism. This finding provides the rationale for use of Em in patients with TAC-induced DM.
The glucose-lowering effect of Em in type 2 DM is that inhibiting the SGLT-2 prevents glucose reabsorption and subsequently induces the elimination of filtered glucose via urine (27, 28) . Therefore, we tested whether a similar effect of SGLT-2 inhibitor can be observed in TACinduced DM. The result of our study demonstrated that the TAC group showed a twofold increase of SGLT-2 expression and urinary glucose excretion compared with the VH group. However, Em significantly decreased SGLT-2 expression and further increased urinary glucose excretion in a dose-dependent manner (Figure 1) . In addition, we evaluated other glucose transporters in kidney and found that Em reduced GLUT-1 and GLUT-2 expression ( Figure 2 ). This finding suggests that SGLT-2 inhibitor increases urinary glucose excretion via SGLT-2 and other glucose transporters as well. Interestingly, Em further increased SGLT-1 expression compared with the TAC group, and this seems to be a compensatory response to decreased SGLT-2 (29, 30) . Indeed, Em significantly decreased TAC-induced hyperglycemia in a dose-dependent manner, and this decrease was accompanied by increased plasma insulin level, recovered islet size, and increased insulin mRNA and insulin secretion measured with GSIS (Figures 3and 4) . This finding suggests that Em is effective in control of TAC-induced hyperglycemia.
In addition to glucose-lowering effect, Em improved renal dysfunction and decreased proteinuria. At a tissue level, Em decreased interstitial fibrosis, extracellular matrix protein (collagen IV), and profibrotic cytokine (TGFb-1) expression in a dose-dependent manner ( Figure 5 ). In addition to the tubulointerstitial area, Em exerted an impact on the glomerular compartment. Em reduced fractional mesangial area, increased podocyte number, and preserved foot process structure ( Figure 6 ). This finding suggests that SGLT-2 inhibition improves TAC-induced glomerular injury, and this may be supported by a report that SGLT-2 inhibition improves podocyte integrity in an experimental model of diabetic nephropathy (31) . We further evaluated the intrarenal renin expression as a renoprotective mechanism of Em because renin-angiotensin system (RAS) activation is an important pathogenic mechanism in the development of TAC-induced renal injury (32, 33) as well as diabetic nephropathy (34, 35) . In our study, we found that increased renin expression in the TAC group was significantly decreased with Em treatment, and this finding was consistent with a previous report that SGLT-2 inhibitor improves diabetic nephropathy by suppressing renal RAS (36) . Taken together, SGLT-2 inhibition has a renoprotective effect in TAC-induced renal injury, and suppression of renal RAS may be involved in this effect. Our study showed that Em decreased TAC-induced pancreatic and renal injury, but its mechanism is undetermined. We and others reported that TAC increases ROS and decreases antioxidant production in a dose-and timedependent manner in beta cells (37) , and drugs that decrease oxidative stress such as statin, N-acetylcysteine, and angiotensin II blockade decrease apoptotic cell death, a common pathway of TAC-induced cell death (19, 23, 38) . Therefore, we evaluated the effect of Em on TAC-induced oxidative stress and apoptotic cell death, and found that Em dramatically decreased 8-OHdG level in serum, kidney, and pancreatic islet and subsequently reduced the number of TUNEL-positive cells and active caspase-3 expression (Figures 7-9 ). This finding suggests that Em protects TAC-induced pancreatic and renal injury, decreasing oxidative stress and subsequent apoptotic cell death. It is still undetermined whether decreased oxidative stress by Em is a secondary effect of reduced glucose level or direct effect of Em on pancreatic islet cells or renal tubular cells. Therefore, we evaluated the effect of Em on the TAC-induced pancreatic and renal injury in vitro system without addition of glucose. In our study, we found that TAC decreased but addition of Em increased cell viability and decreased oxidative stress in a dose-dependent manner in HK-2 cells. However, this protective effect of Em was not observed in TAC-treated INS-1 cells (Figure 10 ). This finding suggests that Em has a direct protective effect on TAC-induced renal tubular injury, but not on pancreatic islet injury, and interaction between Em and SGLT-2 plays an important role in renal protective effect. Our presumption may be supported by recent reports that insulin and ROS increase the expression of SGLT-2 and glucose uptake in proximal tubular cells (39) and SGLT-2 inhibitor protects against ischemia-reperfusion injury by inducing hypoxia-inducible factor 1 (40) . Taken together, the above results, SGLT-2 may play an important role in protecting renal tubular cells against hypoxic injuries under normal glucose conditions, and further study is needed to define its mechanism.
Reduced hyperfiltration by SGLT-2 inhibition has been suggested as the main mechanism in patients with type 2 DM. In clinical trial of type 2 DM, Em caused an initial decrease in the eGFR but completely reversed after the cessation of this study drug, and this result is related to the increased vasoconstriction of afferent arteriole due to increased tubuloglomerular balance (41) . It is well known that TAC-induced renal dysfunction is due to reduced eGFR by persistent vasoconstriction of arterioles (42) . Therefore, we were concerned that Em may aggravate TAC-induced renal dysfunction via further vasoconstrictions of afferent arterioles (43) . However, contrary to our concern, there was no initial decrease of renal function in TAC and Em treatment ( Table 2 ). The reason for initial improvement of renal function by Em is not clear, but we speculate two possibilities. First, TAC may not cause a significant decrease of kidney blood flow in comparison to cyclosporine (44) . Second, reduced hyperfiltration by Em may not be strong to affect renal function in a setting of TAC-induced renal injury. All things considered, our study shows that Em does not deteriorate renal function in TACtreated patients. Another consideration is the blood pressure-lowering effect of Em. However, our results showed no difference of blood pressure among study groups. The reason for no difference of blood pressure is unclear, but it seems to be related to the low-salt diet. We previously confirmed that calcineurin inhibitor treatment in the low-salt diet did not increase blood pressure (15) . Therefore, the renal effect of Em on TAC-induced renal injury is not related to the blood pressure-lowering effect.
Recent clinical trials revealed that Em decreases cardiovascular complication and attenuates progression of kidney disease in patients with type 2 DM (41,45). Cardiovascular complication and progression of kidney disease is the common issue in both patients with type 2 DM and NODAT. The results of our animal and in vitro study suggest that SGLT-2 inhibitor may also be effective in patients with NODAT, but transplant recipients are receiving other diabetogenic immunosuppressive drugs, such as steroid and mammalian target of rapamycin inhibitors (46) . Therefore, a clinical trial is needed to determine whether the observed effect in this study can be extended to renal transplant recipients with NODAT.
In conclusion, SGLT-2 inhibitor is effective in improving TAC-induced hyperglycemia and has a direct protective effect on renal tubular cells. This finding provides confirmation of the clinical usefulness of Em in renal transplant patients with TAC-induced DM.
